Table 3.
Association analysis of DRD2 gene among MDD patients and controls
| SNP | Genotype | patients (n=114) | Control (n=224) | Chi-square Test | ||
|---|---|---|---|---|---|---|
|
| ||||||
| X2 | p | OR (95% CI) | ||||
| rs1799732 (-141delc) | C/C | 98 | 178 | 2.2 | 0.3 | |
| C/- | 12 | 34 | ||||
| -/- | 4 | 12 | ||||
| C/C + C/- vs -/- | 0.6 | 0.5 | 1.6 (0.5-4.9) | |||
| C/C vs C/- + -/- | 2.1 | 0.1 | 1.6 (0.9-2.9) | |||
| rs6277 (C957T) | CC | 102 | 196 | 0.8 | 0.7 | |
| CT | 10 | 24 | ||||
| TT | 2 | 2 | ||||
| CC + CT vs TT | 0.5 | 0.5 | 0.5 (0.7-3.7) | |||
| CC vs CT + TT | 0.1 | 0.8 | 1.1 (0.6-2.3) | |||
| rs1800497 (Taq1A) | CC | 14 | 28 | 1.8 | 0.4 | |
| CT | 50 | 114 | ||||
| TT | 50 | 82 | ||||
| CC + CT vs TT | 1.7 | 0.2 | 0.7 (0.5-1.2) | |||
| CC vs CT + TT | 0.003 | 1.0 | 1.0 (0.5-2.0) | |||
Dominant effect (variant homozygotes + heterozygotes versus wild homozygotes) as analyzed by crosstab analysis; Recessive effect (variant homozygotes versus heterozygotes + wild homozygotes) as analyzed by crosstab analysis; only 2×2 crosstab analysis has OR and 95% CI.